11:39 AM EST - Acasti Pharma Inc. : Announced that company researchers have been invited to present the CaPre® (omega-3 phospholipid) bridging study results in a poster presentation at the National Lipid Association Scientific Sessions in Philadelphia, May 18-21. Acasti will present the results of its 'Phase 1, Single-Dose, Comparative Bioavailability Study of CaPre, a novel Omega-3 Derived from Krill Oil and Lovaza® under Fasting and Fed Conditions.' Acasti Pharma Inc.
shares V.ACST are trading unchanged at $1.70.
